Cas:4362-40-7 UNII:0366925SM9 manufacturer & supplier

Chemical Name:UNII:0366925SM9

CAS.NO:4362-40-7

Synonyms:1,3-Dioxolane, 4-(chloromethyl)-2,2-dimethyl-;4-(CHLOROMETHYL)-2,2-DIMETHYL-1,3-DIOXOLANE;1,3-DIOXOLANE, 4-CHLOROMETHYL-2,2-DIMETHYL-;5-chloromethyl-2,2-dimethyl-1,3-dioxolane;MFCD00046097;UNII:0366925SM9;EINECS 224-452-5

Molecular Formula:C₆H₁₁ClO₂

Molecular Weight:150.603

HS Code:2932999099

Physical and Chemical Properties:

Melting point:N/A

Boiling point:156.0±0.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.421

PSA:18.46000

Exact Mass:150.044754

LogP:0.83

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 1992 3/PG 3

Packing Group:

Contact us for information like 1,3-Dioxolane, 4-(chloromethyl)-2,2-dimethyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 224-452-5 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,3-Dioxolane, 4-(chloromethyl)-2,2-dimethyl- Use and application,4-(CHLOROMETHYL)-2,2-DIMETHYL-1,3-DIOXOLANE technical grade,usp/ep/jp grade.

Related News: From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry. UNII:0366925SM9 manufacturer From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry. UNII:0366925SM9 supplier Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.�� UNII:0366925SM9 vendor The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace. UNII:0366925SM9 factory The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.